Haemonetics Corporation has released its financial results for fiscal year 2025, reporting a 4.0% increase in net revenues compared to fiscal 2024. This growth was mainly driven by the Hospital business, which saw revenue increase by 23.7%, primarily due to recent acquisitions and growth in Interventional Technologies and Blood Management Technologies. In contrast, Blood Center revenue declined by 7.8%, largely due to a decrease in the Whole Blood business following its divestiture. Net income for fiscal 2025 was reported at $167.7 million, marking a 42.6% increase from the previous year. This improvement resulted in a net income per share of $3.33, up from $2.32 in fiscal 2024. The company attributed this increase to operating leverage, the remeasurement of contingent consideration, and gains from the sale of a manufacturing facility, despite incurring transaction and integration costs from recent acquisitions. Provision for income taxes increased to $44.4 million, constituting 20.9% of pre-tax income, compared to $34.3 million or 22.6% the previous year. The results reflect the company's strategic acquisitions and operational adjustments, contributing to the overall financial performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.